Rankings
▼
Calendar
KNSA Q2 2023 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q2 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$71M
+165.0% YoY
Gross Profit
$49M
68.2% margin
Operating Income
-$3M
-4.4% margin
Net Income
$15M
20.9% margin
EPS (Diluted)
$0.21
QoQ Revenue Growth
+47.8%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$484M
Total Liabilities
$73M
Stockholders' Equity
$412M
Cash & Equivalents
$113M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$71M
$27M
+165.0%
Gross Profit
$49M
$17M
+183.7%
Operating Income
-$3M
-$19M
+83.7%
Net Income
$15M
-$20M
+174.9%
Revenue Segments
Product
$54M
76%
Collaboration
$17M
24%
← FY 2023
All Quarters
Q3 2023 →